Advertisement

The Placebo and Nocebo Effect

  • Stephen P. Glasser
  • William Frishman

Abstract

There are four general reasons for clinical improvement in a patient’s condition: (1) natural history of the disease; (2) specific effects of the treatment; (3) regression to the mean; and (4) nonspecific effects of the treatment that are attributable to factors other than the specific active components. The latter effect is included under the heading ‘placebo effect’. In this chapter the placebo effect will be discussed, with some emphasis on regression to the mean. Placebos (‘I will please’) and their lesser known counterpart’s nocebo’s (I will harm’) are sham treatments. The difference is in the response to the inert therapy. A beneficial response to an inert substance is a placebo response; a side effect to an inert substance is a nocebo response.

Keywords

Placebo Effect Placebo Control Placebo Response Excellent Adherence Aspirin Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. May 25, 1994; 271(20):1609–1614.PubMedCrossRefGoogle Scholar
  2. 2.
    Benson H, Epstein MD. The placebo effect. A neglected asset in the care of patients. JAMA. June 23, 1975; 232(12):1225–1227.PubMedCrossRefGoogle Scholar
  3. 3.
    Melmon K, Morrelli H, Hoffman B, Mierenberg D, eds. Melmon and Morrelli’s Clinical Pharmacology: Basic Principles in Therapeutics. 3rd ed. New York: McGraw-Hill; 1992; pp. 896.Google Scholar
  4. 4.
    Packer M, Medina N, Yushak M. Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. Circulation. Apr 1985; 71(4):761–766.PubMedGoogle Scholar
  5. 5.
    Chalmers TC. Prophylactic treatment of Wilson’s disease. N Engl J Med. Apr 18, 1968; 278(16):910–911.PubMedGoogle Scholar
  6. 6.
    Garrison FH. History of Medicine. 4th ed. Philadelphia, PA: Saunders; 1929.Google Scholar
  7. 7.
    Rana JS, Mannam A, Donnell-Fink L, Gervino EV, Sellke FW, Laham RJ. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol. June 15, 2005; 95(12):1456–1459.PubMedCrossRefGoogle Scholar
  8. 8.
    Randolph E, ed. Stedman’s Medical Dictionary. Baltimore, MD: Lippincott Williams & Wilkins; 1990.Google Scholar
  9. 9.
    White L, Tursky B, Schwartz G. Placebo: Theory, Research, and Mechanisms. New York: Guilford Press; 1985.Google Scholar
  10. 10.
    Shapiro AK. Factors contributing to the placebo effect: their implications for psychotherapy. AM J Pschother. 1961; 18:73–88.Google Scholar
  11. 11.
    Byerly H. Explaining and exploiting placebo effects. Perspect Biol Med. Spring 1976; 19(3):423–436.PubMedGoogle Scholar
  12. 12.
    Lind JA. A treatise of the scurvy. Edinburgh: Edinburgh University Press; 1753.Google Scholar
  13. 13.
    Hill AB. The clinical trial. Br Med Bull. 1951; 7(4):278–282.PubMedGoogle Scholar
  14. 14.
    Beecher HK. The powerful placebo. J Am Med Assoc. Dec 24, 1955; 159(17):1602–1606.PubMedGoogle Scholar
  15. 15.
    Lasagna L, Mosteller F, Von Felsinger JM, Beecher HK. A study of the placebo response. Am J Med. June 1954; 16(6):770–779.PubMedCrossRefGoogle Scholar
  16. 16.
    Wolf S, Pinsky RH. Effects of placebo administration and occurrence of toxic reactions. J Am Med Assoc. May 22, 1954; 155(4):339–341.PubMedGoogle Scholar
  17. 17.
    Davis JM. Don’t let placebos fool you. Postgrad Med. Sept 15, 1990; 88(4):21–24.PubMedGoogle Scholar
  18. 18.
    Nies A, Spielberg S. Principles of therapeutics. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996.Google Scholar
  19. 19.
    Makuch RW, Johnson MF. Dilemmas in the use of active control groups in clinical research. IRB. Jan–Feb 1989; 11(1):1–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Galton F. Regression towards mediocrity in hereditary stature. J Anthropol Inst. 1886; 15:246–263.Google Scholar
  21. 21.
    Ederer F. Serum cholesterol changes: effects of diet and regression toward the mean. J Chronic Dis. May 1972; 25(5):277–289.PubMedCrossRefGoogle Scholar
  22. 22.
    Davis CE. The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol. Nov 1976; 104(5):493–498.PubMedGoogle Scholar
  23. 23.
    The National Diet-Heart Study Final Report. Circulation. Mar 1968; 37(3 Suppl):I1–428.Google Scholar
  24. 24.
    Yudkin PL, Stratton IM. How to deal with regression to the mean in intervention studies. Lancet. Jan 27, 1996; 347(8996):241–243.PubMedCrossRefGoogle Scholar
  25. 25.
    Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens. June 2001; 14(6 Pt 1):546–552.PubMedCrossRefGoogle Scholar
  26. 26.
    Oh VMS. Magic or medicine? Clinical pharmacological basis of placebo medication. Ann Acad Med (Singapore). 1991; 20:31–37.Google Scholar
  27. 27.
    Kelly JP. Anatomical organization of the nervous system. In: Kandel ER, Schwartz JH, Jessel TM, eds. Principles of Neural Science. 3rd ed. New York: Elsevier; 1991; pp. 276–292.Google Scholar
  28. 28.
    Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain. Oct 1990; 43(1):121–128.PubMedCrossRefGoogle Scholar
  29. 29.
    Levine JD, Gordon NC, Bornstein JC, Fields HL. Role of pain in placebo analgesia. Proc Natl Acad Sci USA. July 1979; 76(7):3528–3531.PubMedCrossRefGoogle Scholar
  30. 30.
    Hersh EV, Ochs H, Quinn P, MacAfee K, Cooper SA, Barasch A. Narcotic receptor blockade and its effect on the analgesic response to placebo and ibuprofen after oral surgery. Oral Surg Oral Med Oral Pathol. May 1993; 75(5):539–546.PubMedCrossRefGoogle Scholar
  31. 31.
    Kojo I. The mechanism of the psychophysiological effects of placebo. Med Hypotheses. Dec 1988; 27(4):261–264.PubMedCrossRefGoogle Scholar
  32. 32.
    Egbert LD, Battit GE, Welch CE, Bartlett MK. Reduction of postoperative pain by encouragement and instruction of patients. A study of doctor-patient rapport. N Engl J Med. Apr 16, 1964; 270:825–827.PubMedGoogle Scholar
  33. 33.
    Amsterdam EA, Wolfson S, Gorlin R. New aspects of the placebo response in angina pectoris. Am J Cardiol. Sept 1969; 24(3):305–306.PubMedCrossRefGoogle Scholar
  34. 34.
    Glasser SP, Clark PI, Lipicky RJ, Hubbard JM, Yusuf S. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA. Mar 27, 1991; 265(12):1550–1554.PubMedCrossRefGoogle Scholar
  35. 35.
    Lipicky R, DeFelice A, Gordon M, et al. Placebo in Hypertension Adverse Reaction Meta-Analysis(PHARM). Circulation. 2003; 17(Supplement):IV–452.Google Scholar
  36. 36.
    Boissel JP, Philippon AM, Gauthier E, Schbath J, Destors JM. Time course of long-term placebo therapy effects in angina pectoris. Eur Heart J. Dec 1986; 7(12):1030–1036.PubMedGoogle Scholar
  37. 37.
    McGraw BF, Hemberger JA, Smith AL, Schroeder JS. Variability of exercise performance during long-term placebo treatment. Clin Pharmacol Ther. Sept 1981; 30(3):321–327.PubMedGoogle Scholar
  38. 38.
    Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Steering committee, transdermal nitroglycerin cooperative study. Am J Cardiol. Nov 15, 1991; 68(13):1263–1273.Google Scholar
  39. 39.
    Beecher HK. Surgery as placebo. A quantitative study of bias. JAMA. July 1, 1961; 176:1102–1107.PubMedGoogle Scholar
  40. 40.
    Diamond EG, Kittle CF, Crockett JE. Evaluation of internal mammary artery ligation and sham procedures in angina pectoris. Circulation. 1958; 18:712–713.Google Scholar
  41. 41.
    Diamond EG, Kittle CF, Crockett JE. Comparison of internal mammary artery ligation and sham operation for angina pectoris. Am J Cardiol. 1960; 5:484–486.Google Scholar
  42. 42.
    Cobb LA. Evaluation of internal mammary artery ligation by double-blind technic. N Engl J Med. 1989; 260:1115–1118.Google Scholar
  43. 43.
    Carver JR, Samuels F. Sham therapy in coronary artery disease and atherosclerosis. Pract. Cardiol. 1988; 14:81–86.Google Scholar
  44. 44.
    van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation. Sept 1994; 90(3): 1194–1199.PubMedGoogle Scholar
  45. 45.
    Packer M. The placebo effect in heart failure. Am Heart J. Dec 1990; 120(6 Pt 2): 1579–1582PubMedCrossRefGoogle Scholar
  46. 46.
    Archer TP, Leier CV. Placebo treatment in congestive heart failure. Cardiology. 1992; 81(2–3):125–133.PubMedCrossRefGoogle Scholar
  47. 47.
    Randomised controlled trial of treatment for mild hypertension: design and pilot trial. Report of medical research council working party on mild to moderate hypertension. Br Med J. June 4, 1977; 1(6074):1437–1440.CrossRefGoogle Scholar
  48. 48.
    Gould BA, Mann S, Davies AB, Altman DG, Raftery EB. Does placebo lower blood-pressure? Lancet. Dec 19–26, 1981; 2(8260–8261):1377–1381.PubMedCrossRefGoogle Scholar
  49. 49.
    Martin MA, Phillips CA, Smith AJ. Acebutolol in hypertension–double-blind trial against placebo. Br J Clin Pharmacol. Oct 1978; 6(4):351–356.PubMedGoogle Scholar
  50. 50.
    Moutsos SE, Sapira JD, Scheib ET, Shapiro AP. An analysis of the placebo effect in hospitalized hypertensive patients. Clin Pharmacol Ther. Sept–Oct 1967; 8(5):676–683.PubMedGoogle Scholar
  51. 51.
    Myers MG, Lewis GR, Steiner J, Dollery CT. Atenolol in essential hypertension. Clin Pharmacol Ther. May 1976; 19(5 Pt 1):502–507.PubMedGoogle Scholar
  52. 52.
    Pugsley DJ, Nassim M, Armstrong BK, Beilin L. A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension. Br J Clin Pharmacol. Jan 1979; 7(1):63–68.PubMedGoogle Scholar
  53. 53.
    A DOUBLE blind control study of antihypertensive agents. I. Comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, chlorisondamine, mecamyamine, and pentolinium tartrate. Arch Intern Med. July 1960; 106:81–96.Google Scholar
  54. 54.
    Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 119 mmHg by Veterans Administration cooperative study group on antihypertensive agents. JAMA. 1967; 202:116–122.CrossRefGoogle Scholar
  55. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. Aug 17, 1970; 213(7):1143–1152.Google Scholar
  56. 56.
    Hansson L, Aberg H, Karlberg BE, Westerlund A. Controlled study of atenolol in treatment of hypertension. Br Med J. May 17, 1975; 2(5967):367–370.PubMedCrossRefGoogle Scholar
  57. 57.
    Wilkinson PR, Raftery EB. A comparative trial of clonidine, propranolol and placebo in the treatment of moderate hypertension. Br J Clin Pharmacol. June 1977; 4(3):289–294.PubMedGoogle Scholar
  58. 58.
    Chasis H, Goldring W, Schreiner GE, Smith HW. Reassurance in the management of benign hypertensive disease. Circulation. Aug 1956; 14(2):260–264.PubMedGoogle Scholar
  59. 59.
    Raftery EB, Gould BA. The effect of placebo on indirect and direct blood pressure measurements. J Hypertens Suppl. Dec 1990; 8(6):S93–100.Google Scholar
  60. 60.
    Mutti E, Trazzi S, Omboni S, Parati G, Mancia G. Effect of placebo on 24-h non-invasive ambulatory blood pressure. J Hypertens. Apr 1991; 9(4):361–364.PubMedCrossRefGoogle Scholar
  61. 61.
    Dupont AG, Van der Niepen P, Six RO. Placebo does not lower ambulatory blood pressure. Br J Clin Pharmacol. July 1987; 24(1):106–109.PubMedGoogle Scholar
  62. 62.
    O’Brien E, Cox JP, O’Malley K. Ambulatory blood pressure measurement in the evaluation of blood pressure lowering drugs. J Hypertens. Apr 1989; 7(4):243–247.PubMedCrossRefGoogle Scholar
  63. 63.
    Casadei R, Parati G, Pomidossi G, et al. 24-hour blood pressure monitoring: evaluation of Spacelabs 5300 monitor by comparison with intra-arterial blood pressure recording in ambulant subjects. J Hypertens. Oct 1988; 6(10):797–803.PubMedCrossRefGoogle Scholar
  64. 64.
    Portaluppi F, Strozzi C, degli Uberti E, et al. Does placebo lower blood pressure in hypertensive patients? A noninvasive chronobiological study. Jpn Heart J. Mar 1988; 29(2):189–197.PubMedGoogle Scholar
  65. 65.
    Sassano P, Chatellier G, Corvol P, Menard J. Influence of observer’s expectation on the placebo effect in blood pressure trials. Curr Ther Res. 1987; 41:304–312.Google Scholar
  66. 66.
    Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. June 26, 1991; 265(24):3255–3264.CrossRefGoogle Scholar
  67. 67.
    Davis BR, Wittes J, Pressel S, et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Control Clin Trials. Oct 1993; 14(5):350–361.PubMedCrossRefGoogle Scholar
  68. 68.
    Al-Khatib SM, Califf RM, Hasselblad V, Alexander JH, McCrory DC, Sugarman J. Medicine. Placebo-controls in short-term clinical trials of hypertension. Science. June 15, 2001; 292(5524):2013–2015.PubMedCrossRefGoogle Scholar
  69. 69.
    Michelson EL, Morganroth J. Spontaneous variability of complex ventricular arrhythmias detected by long-term electrocardiographic recording. Circulation. Apr 1980; 61(4):690–695.PubMedGoogle Scholar
  70. 70.
    Morganroth J, Borland M, Chao G. Application of a frequency definition of ventricular proarrhythmia. Am J Cardiol. Jan 1, 1987; 59(1):97–99.PubMedCrossRefGoogle Scholar
  71. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. Aug 10, 1989; 321(6):406–412.Google Scholar
  72. 72.
    Capone RJ, Pawitan Y, el-Sherif N, et al. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol. Nov 15, 1991; 18(6):1434–1438.PubMedCrossRefGoogle Scholar
  73. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. Oct 30, 1980; 303(18):1038–1041.Google Scholar
  74. 74.
    Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. Sept 1, 1990; 336(8714):542–545.PubMedCrossRefGoogle Scholar
  75. 75.
    Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA. Aug 11, 1993; 270(6):742–744.PubMedCrossRefGoogle Scholar
  76. 76.
    The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. Jan 20, 1984; 251(3):365–374.CrossRefGoogle Scholar
  77. 77.
    Sackett DL, Haynes RB, Gibson E, Johnson A. The problem of compliance with antihypertensive therapy. Pract. Cardiol. 1976; 2:35–39.Google Scholar
  78. 78.
    Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians’ Health Study. Arch Intern Med. Dec 12–26, 1994; 154(23):2649–2657.PubMedGoogle Scholar
  79. 79.
    Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol. Mar 15, 1999; 83(6):903–907.PubMedCrossRefGoogle Scholar
  80. 80.
    Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. Aug 11, 1994; 331(6):394–398.PubMedCrossRefGoogle Scholar
  81. 81.
    Clark PI, Leaverton PE. Scientific and ethical issues in the use of placebo controls in clinical trials. Annu Rev Public Health. 1994; 15:19–38.PubMedCrossRefGoogle Scholar
  82. 82.
    Schechter C. The use of placebo controls. N Engl J Med. Jan 5 1995; 332(1):60; author reply 62.PubMedCrossRefGoogle Scholar
  83. 83.
    Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med. Aug 15, 1993; 119(4):329–335.PubMedGoogle Scholar
  84. 84.
    Drici MD, Raybaud F, De Lunardo C, Iacono P, Gustovic P. Influence of the behaviour pattern on the nocebo response of healthy volunteers. Br J Clin Pharmacol. Feb 1995; 39(2):204–206.PubMedGoogle Scholar
  85. 85.
    Roberts AH. The powerful placebo revisited: magnitude of nonspecific effects. Mind/Body Medicine. 1995; 1:35–43.Google Scholar
  86. 86.
    Emanuel E, Miller F. The ethics of placebo-controlled trials – a middle ground. NEJM. 2001; 345:915–918.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V 2008

Authors and Affiliations

  • Stephen P. Glasser
    • 1
  • William Frishman
    • 2
  1. 1.Univesity of Alabama at Birmingham, Birmingham, AlabamaBirmingham
  2. 2.The Department of MedicineNew York Medical CollegeNew York City

Personalised recommendations